Skip to main content
Michael Nall, MD, Allergy & Immunology, Louisville, KY

Michael Sanford Nall MD


Physician

Join to View Full Profile
  • 9113 Leesgate RdLouisville, KY 40222

  • Phone+1 502-426-1621

  • Fax+1 502-426-7906

Dr. Nall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Louisville School of Medicine
    University of Louisville School of MedicineResidency, Pediatrics, 1967 - 1969
  • University of Louisville School of Medicine
    University of Louisville School of MedicineResidency, Pediatrics, 1966 - 1967
  • University of Louisville School of Medicine
    University of Louisville School of MedicineInternship, Transitional Year, 1965 - 1966
  • University of Kentucky College of Medicine
    University of Kentucky College of MedicineClass of 1965

Certifications & Licensure

  • KY State Medical License
    KY State Medical License 1966 - 2026
  • IN State Medical License
    IN State Medical License 2011 - 2019
  • Allergy & Immunology
    American Board of Allergy and Immunology Allergy & Immunology
  • Pediatrics
    American Board of Pediatrics Pediatrics

Publications & Presentations

PubMed

Press Mentions

  • Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers
    Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer BiomarkersJuly 6th, 2021
  • Biocept Reports 2020 Fourth Quarter and Full Year Financial Results
    Biocept Reports 2020 Fourth Quarter and Full Year Financial ResultsMarch 29th, 2021
  • Biocept to Present Study Results from Target Selector™ Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy Meeting
    Biocept to Present Study Results from Target Selector™ Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy MeetingOctober 1st, 2020
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: